Literature DB >> 22895852

Influence of type 1 diabetes genes on disease progression: similarities and differences between countries.

Johanna Lempainen1, Jorma Ilonen.   

Abstract

Type 1 diabetes (T1D) is an autoimmune disease causing the destruction of pancreatic beta cells. The onset of clinical T1D is preceded by a time period called pre-diabetes, the duration of which varies widely. However, not all subjects developing beta-cell autoimmunity progress to clinical T1D. The inherited risk for T1D is determined by the human leukocyte antigen (HLA) class II genes, HLA class I genes, and several loci outside the HLA area. Although the role of the genetic risk variants in disease pathogenesis is not completely understood, some of the variants affecting disease risk are thought to influence the initiation of beta-cell autoimmunity whereas others seem to play a role during the later stages of the autoimmune process. In this review we describe the current knowledge on the genetic factors mediating the fate of already-established beta-cell autoimmunity and the rate of beta-cell destruction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895852     DOI: 10.1007/s11892-012-0310-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  68 in total

Review 1.  Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?

Authors:  Garth L Burn; Lena Svensson; Cristina Sanchez-Blanco; Manoj Saini; Andrew P Cope
Journal:  FEBS Lett       Date:  2011-04-20       Impact factor: 4.124

2.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.

Authors:  Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough
Journal:  Nature       Date:  2003-04-30       Impact factor: 49.962

3.  The Karlsburg type 1 diabetes risk study of a normal schoolchild population: association of beta-cell autoantibodies and human leukocyte antigen-DQB1 alleles in antibody-positive individuals.

Authors:  Michael Schlosser; Martina Strebelow; Ralf Wassmuth; Marie-Luise Arnold; Isabel Breunig; Ilona Rjasanowski; Brigitte Ziegler; Manfred Ziegler
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

4.  Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype.

Authors:  A Petrone; A Galgani; M Spoletini; I Alemanno; S Di Cola; G Bassotti; A Picardi; S Manfrini; J Osborn; P Pozzilli; R Buzzetti
Journal:  Diabetes Metab Res Rev       Date:  2005 May-Jun       Impact factor: 4.876

5.  HLA-DR4 subtype and -B alleles in DQB1*0302-positive haplotypes associated with IDDM. The Childhood Diabetes in Finland Study Group.

Authors:  H Reijonen; S Nejentsev; J Tuokko; S Koskinen; E Tuomilehto-Wolf; H K Akerblom; J Ilonen
Journal:  Eur J Immunogenet       Date:  1997-10

6.  The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter.

Authors:  J Andrejeva; K S Childs; D F Young; T S Carlos; N Stock; S Goodbourn; R E Randall
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

7.  Reduced CD4+T cell activation in children with type 1 diabetes carrying the PTPN22/Lyp 620Trp variant.

Authors:  Johanna Aarnisalo; Andras Treszl; Peter Svec; Jane Marttila; Viveka Oling; Olli Simell; Mikael Knip; Anna Körner; Laszlo Madacsy; Barna Vasarhelyi; Jorma Ilonen; Robert Hermann
Journal:  J Autoimmun       Date:  2008-03-04       Impact factor: 7.094

8.  Disease-associated autoantibodies and HLA-DQB1 genotypes in children with newly diagnosed insulin-dependent diabetes mellitus (IDDM). The Childhood Diabetes in Finland Study Group.

Authors:  E Sabbah; K Savola; P Kulmala; H Reijonen; R Veijola; P Vähäsalo; J Karjalainen; J Ilonen; H K Akerblom; M Knip
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

9.  HLA genes associated with autoimmunity and progression to disease in type 1 diabetes.

Authors:  B D Tait; P G Colman; G Morahan; L Marchinovska; E Dore; S Gellert; M C Honeyman; K Stephen; A Loth
Journal:  Tissue Antigens       Date:  2003-02

10.  Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A.

Authors:  Sergey Nejentsev; Joanna M M Howson; Neil M Walker; Jeffrey Szeszko; Sarah F Field; Helen E Stevens; Pamela Reynolds; Matthew Hardy; Erna King; Jennifer Masters; John Hulme; Lisa M Maier; Deborah Smyth; Rebecca Bailey; Jason D Cooper; Gloria Ribas; R Duncan Campbell; David G Clayton; John A Todd
Journal:  Nature       Date:  2007-11-14       Impact factor: 49.962

View more
  2 in total

1.  Changes in Zinc Transporter 8 Autoantibodies Following Type 1 Diabetes Onset: The Type 1 Diabetes Genetics Consortium Autoantibody Workshop.

Authors:  Janet M Wenzlau; Lisa M Frisch; John C Hutton; Pamela R Fain; Howard W Davidson
Journal:  Diabetes Care       Date:  2015-10       Impact factor: 19.112

2.  Dynamics of Islet Autoantibodies During Prospective Follow-Up From Birth to Age 15 Years.

Authors:  Petra M Pöllänen; Samppa J Ryhänen; Jorma Toppari; Jorma Ilonen; Paula Vähäsalo; Riitta Veijola; Heli Siljander; Mikael Knip
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.